References
- Food and Drug Administration (FDA). Workshop on Non-clinical Safety Evaluation of Preventative Vaccines: Recent Advances and Regulatory Considerations. 2002 [cited 2011 May 30]. Available from:http://www.fda.gov/downloads/biologicsbloodvaccines/newsevents/workshopsmeetingsconferences/transcriptsminutes/ucm054459.pdf
- The Australian Immunisation Handbook, 9th edition. 1.3. Pre-vaccination Procedures. 1.3.3 Valid consent [cited 2011 September 15]. Available from: http://www.health.gov.au/internet/immunise/publishing.nsf/Content/handbook-consent
- UK Guidance on Best Practice in Vaccine Administration. 2001 [cited 2011 September 15]. Available from: http://www.rcn.org.uk/__data/assets/pdf_file/0010/78562/001981.pdf
- Centers for Disease Control and Prevention. Vaccine Information Statements (VISs). Last modified December 6, 2010 [cited 2011 April 5]. Available from: http://www.cdc.gov/vaccines/pubs/vis/vis-faqs.htm
- Merck&Co. Protection with Gardasil [cited 2011 July 20]. Available from: http://www.gardasil.com/what-is-gardasil/cervical-cancer-vaccine/index.html
- Centers for Disease Control and Prevention. Information from FDA and CDC on Gardasil and its Safety (Archived), 2008 [cited 2011 January 25]. Available from: http://www.cdc.gov/vaccinesafety/Vaccines/HPV/HPVArchived.html
- Centers for Disease Control and Prevention (CDC). Reports of Health Concerns Following HPV Vaccination. Last updated: June 28 2011 [cited 2011 July 22]. Available from: http://www.cdc.gov/vaccinesafety/vaccines/hpv/gardasil.html
- Villa LL, Costa RL, Petta CA, Andrade RP, Paavonen J, Iversen OE, . High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up. Br J Cancer. 2006;95:1459–66.
- De Carvalho N, Teixeira J, Roteli-Martins CM, Naud P, De Borba P, Zahaf T, . Sustained efficacy and immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine up to 7.3 years in young adult women. Vaccine. 2010;28:6247–55.
- Harper DM, Williams KB. Prophylactic HPV vaccines: current knowledge of impact on gynecologicpremalignancies. Discov Med. 2010;10: 7–l17.
- Haug C. The risks and benefits of HPV vaccination. JAMA. 2009;302:795–6.
- Flogging gardasil. Nat Biotechnol. 2007;25:261.
- Markowitz LE, Dunne EF, Saraiya M, Lawson HW, Chesson H, Unger ER. Quadrivalenthuman papillomavirus vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2007;56:1–24.
- Paavonen J, Naud P, Salmeron J, Wheeler CM, Chow SN, Apter D, . Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet. 2009;374:301–14.
- The FUTURE II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med. 2007;356:1915–27.
- Franco EL, Villa LL, Sobrinho JP, Prado JM, Rousseau MC, Désy M, . Epidemiology of acquisition and clearance of cervical human papillomavirus infection in women from a high-risk area for cervical cancer. J Infect Dis. 1999;180:1415–23.
- HoGY, Bierman R, Beardsley L, Chang CJ, Burk RD. Natural history of cervicovaginal papillomavirus infection in young women. N Engl J Med. 1998;338:423–8.
- Moscicki AB, Shiboski S, Broering J, Powell K, Clayton L, Jay N, . The natural history of human papillomavirus infection as measured by repeated DNA testing in adolescent and young women. J Pediatr. 1998;132:277–84.
- Ostor AG. Natural history of cervical intraepithelial neoplasia: a critical review. Int J Gynecol Pathol. 1993;12:186–92.
- Garland SM, Hernandez-Avila M, Wheeler CM, Perez G, Harper DM, Leodolter S, .; FUTURE I Investigators.Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med. 2007;356:1928–43.
- Hildesheim A, Herrero R, Wacholder S, Rodriguez AC, Solomon D, Bratti MC, . Effect of human papillomavirus 16/18 L1viruslike particle vaccine among young women with preexisting infection: a randomized trial. JAMA. 2007;298:743–53.
- Food and Drug Administration (FDA). Gardasil (Human Papillomavirus Vaccine) Questions and Answers, June 8, 2006 [cited 2011 September 27]. Available from: http://www.fda.gov/BiologicsBloodVaccines/Vaccines/QuestionsaboutVaccines/ucm096052.htm
- Medicines and Healthcare productsRegulatory Agency (MHRA). Paper provided by MHRA for Joint Committee on Vaccination and Immunisation June 2010: Vaccine associated suspected adverse reactions reported via the Yellow Card scheme during 2009 [cited 2011 July 17]. Available from: http://www.dh.gov.uk/prod_consum_dh/groups/dh_digitalassets/@dh/@ab/documents/digitalasset/dh_118753.pdf
- Irish Medicines Board (IMB). Update on national monitoring experience with Gardasil. 11th November 2010 [cited 2011 July 17]. Available from: http://www.imb.ie/images/uploaded/documents/IMB_Gardasil_WebUpdate_11Nov2010.pdf
- Campos NG, Kim JJ, Castle PE, Ortendahl JD, O'Shea M, Diaz M, . Health and economic impact of HPV 16/18 vaccination and cervical cancer screening in Eastern Africa. Int J Cancer. 2011 Jun 29. [Epub ahead of print]
- Lawrence G, Gold MS, Hill R, Deeks S, Glasswell A, Mc Intyre PB. Annual report: Surveillance of adverse events following immunisation in Australia, 2007. Commun Dis Intell. 2008;32(4)71–87.
- National Vaccine Information Center. An Analysis by the National Vaccine Information Center of Gardasil &Menactra Adverse Event Reports to the Vaccine Adverse Events Reporting System (VAERS). February 2009 [cited 2011 January 25]. Available from: http://www.nvic.org/Downloads/NVICGardasilvsMenactraVAERSReportFeb-2009u.aspx
- Menzies R, Mahajan D, Gold MS, Roomiani I, Mc Intyre P, Lawrence G. Annual report: Surveillance of adverse events following immunisation in Australia, 2008. Commun Dis Intell. 2009;33:365–81. Available from: http://www.health.gov.au/internet/main/publishing.nsf/Content/cdi3304
- Mahajan D, Roomiani I, Gold MS, Lawrence GL, McIntyre PB, Menzies RI. Annual report: Surveillance of adverse events following immunisation in Australia, 2009. Comm Dis Intell. 2010;34:259–76. Available from: http://www.health.gov.au/internet/main/publishing.nsf/Content /cdi3403-1
- Slade BA, Leidel L, Vellozzi C, Woo EJ, Hua W, Sutherland A, . Postlicensure safety surveillance for quadrivalent human papillomavirus recombinant vaccine. JAMA. 2009;302:750–7.
- Medicines and Healthcare productsRegulatory Agency (MHRA). Paper provided by MHRA for Joint Committee on Vaccination and Immunisation June 2009: Vaccine associated suspected adverse reactions reported via the Yellow Card scheme during 2008 [cited 2011 July 17]. Available from: http://www.dh.gov.uk/prod_consum_dh/groups/dh_digitalassets/@dh/@ab/documents/digitalasset/dh_110017.pdf
- Database of the Netherlands Pharmacovigilance Centre Lareb. Overview adverse events following immunization in association with Cervarix.February 3, 2010 [cited 2011 July 24]. Available from: http://www.lareb.nl/documents/kwb_2010_2_cerva.pdf
- Irish Medicines Board (IMB). Update on national monitoring experience with Gardasil. 9th February 2011 [cited 2011 July 17]. Available from: http://www.imb.ie/images/uploaded/documents/IMB_Gardasil_WebUpdate_09Feb2011.pdf
- Agence Francaise de Securite Sanitaire des Produits de Sante (AFSSAPS). Vaccinscontre les infections dûes à certains papillomavirus humains (HPV). Gardasil®: Troisièmebilan du plan de gestion des risqueseuropéenet national (12/07/2011) [cited 2011 July 24]. Available from: http://www.afssaps.fr/Dossiers-thematiques/Vaccins/Vaccins-contre-les-infections-dues-a-certains-papillomavirus-humains-HPV/%28offset%29/2
- CDC WONDER VAERS Request [cited 2011 September 15]. Available from: http://wonder.cdc.gov/vaers.html
- Chustecka Z. HPV Vaccine: Debate Over Benefits, Marketing, and New Adverse Event Data. Medscape Med News. 2009[cited 2011 January 25]. Available from: http://www.medscape.com/viewarticle/707634
- Food and Drug Administration Vaccines and Related Biological Products Advisory Committee (VRBPAC) Background Document: Gardasil™ HPV Quadrivalent Vaccine. May 18, 2006 VRBPAC Meeting [cited 2011 September 15]. Available from: http://www.fda.gov/ohrms/dockets/ac/06/briefing/2006-4222B3.pdf
- Health Canada. Human Papillomavirus (HPV). Updated August 2010 [cited 2011 April 4]. Available from: http://www.hc-sc.gc.ca/hl-vs/iyh-vsv/diseases-maladies/hpv-vph-eng.php
- Australian Government, Department of Health and Ageing, Therapeutic Goods Administration. Human papillomavirus vaccine (GARDASIL), Advice from the Therapeutic Goods Administration. Updated 24 June2010 [cited 2011 July 24]. Available from: http://www.tga.gov.au/safety/alerts-medicine-gardasil-070624.htm
- Verstraeten T, Descamps D, David MP, Zahaf T, Hardt K, Izurieta P, . Analysis of adverse events of potential autoimmune aetiology in a large integrated safety database of AS04 adjuvanted vaccines. Vaccine. 2008;26:6630–8.
- Shoenfeld Y, Agmon-Levin N. ‘ASIA’—Autoimmune/inflammatory syndrome induced by adjuvants. J Autoimmun. 2011;36:4–8.
- Israeli E, Agmon-Levin N, Blank M, Shoenfeld Y. Adjuvants and autoimmunity. Lupus. 2009;18:1217–25.
- Cohen AD, Shoenfeld Y. Vaccine-induced autoimmunity. J Autoimmun. 1996;9:699–703.
- Agmon-Levin N, Paz Z, Israeli E, Shoenfeld Y. Vaccines and autoimmunity. Nat Rev Rheumatol. 2009;5:648–52.
- Gandey A. Report of Motor Neuron Disease After HPV Vaccine. Medscape Med News. 2009 [cited 2011 January 25]. Available from: http://www.medscape.com/viewarticle/711461
- Löwer J. Can we still recommend HPV vaccination? MMWFortschr Med. 2008;150:6.
- Mendoza Plasencia Z, Gonzalez Lopez M, Fernandez Sanfiel ML, Muniz Montes JR. [Acute disseminated encephalomyelitis with tumefactive lesions after vaccination against human papillomavirus]. Neurologia. 2010;25:58–9.
- Wildemann B, Jarius S, Hartmann M, RegulaJU, Hametner C. Acute disseminated encephalomyelitis following vaccination against human papilloma virus. Neurology. 2009;72:2132–3.
- Schaffer V, Wimmer S, Rotaru I, Topakian R, Haring HP, Aichner FT. HPV vaccine: a cornerstone of female health a possible cause of ADEM? J Neurol. 2008;255:1818–20.
- Sutton I, Lahoria R, Tan IL, Clouston P, Barnett MH. CNS demyelination and quadrivalent HPV vaccination. Mult Scler. 2009;15:116–9.
- Chang J, Campagnolo D, Vollmer TL, Bomprezzi R. Demyelinating disease and polyvalent human papilloma virus vaccination. J NeurolNeurosurg Psychiatry. 2010:1–3.
- Alvarez-Soria MJ, Hernandez-Gonzalez A, Carrasco-Garcia de Leon S, Del Real-Francia MA, Gallardo-Alcaniz MJ, Lopez-Gomez JL. [Demyelinating disease and vaccination of the human papillomavirus]. Rev Neurol. 2011;52:472–6.
- McCarthy JE, Filiano J. Opsoclonus Myoclonus after human papilloma virus vaccine in a pediatric patient. Parkinsonism Relat Disord. 2009;15: 792–4.
- Mosnaim AD, Abiola R, Wolf ME, Perlmuter LC. Etiology and risk factors for developing orthostatic hypotension. Am J Ther. 2009;17:86–91.
- Debeer P, De Munter P, Bruyninckx F, Devlieger R. Brachial plexus neuritis following HPV vaccination. Vaccine. 2008;26:4417–9.
- Cohen SM. Multiple evanescent white dot syndrome after vaccination for human papilloma virus and meningococcus. J Pediatr Ophthalmol Strabismus. 2009:1–3.
- Das A, Chang D, Biankin AV, Merrett ND. Pancreatitis following human papillomavirus vaccination. Med J Aust. 2008;189:178.
- Brotherton JM, Gold MS, Kemp AS, McIntyre PB, Burgess MA, >Campbell-Lloyd S. Anaphylaxis following quadrivalent human papillomavirus vaccination. CMAJ. 2008;179:525–33.
- Blitshteyn S. Postural tachycardia syndrome after vaccination with Gardasil [letter to the editor]. Eur J Neurol. 2010;17:e52.
- Dale RC, Brilot F, Banwell B. Pediatric central nervous system inflammatory demyelination: acute disseminated encephalomyelitis, clinically isolated syndromes, neuromyelitisoptica, and multiple sclerosis. Curr Opin Neurol. 2009;22:233–40.
- Low PA, Sandroni P, Joyner M, Shen WK. Postural tachycardia syndrome (POTS). J Cardiovasc Electrophysiol. 2009;20:352–8.
- Medicines and Healthcare products Regulatory Agency (MHRA). Suspected adverse reactions received by the MHRA. Cervarix Human papillomavirus (HPV) vaccine (as of 29 July 2010) [cited 2011 July 24]. Available from: http://www.mhra.gov.uk/PrintPreview/DefaultSplashPP/CON023340?ResultCount = 10&DynamicListQuery = &DynamicListSortBy = xCreationDate&DynamicListSortOrder = Desc&Dynamic ListTitle = &PageNumber = 1&Title = Human%20papillomavirus%20%28HPV%29%20vaccine
- Food and Drug Administration. Inside Clinical Trials: Testing Medical Products in People. Last updated May 2009 [cited 2011 April 4]. Available from: http://www.fda.gov/Drugs/ResourcesForYou/Consumers/ucm143531.htm
- Golomb BA, Erickson LC, Koperski S, Sack D, Enkin M, Howick J. What's in placebos: who knows? Analysis of randomized, controlled trials. Ann Intern Med. 2010;153:532–5.
- Harper DM, Franco EL, Wheeler C, Ferris DG, Jenkins D, Schuind A, . Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet. 2004;364:1757–65.
- Harper DM, Franco EL, Wheeler CM, Moscicki AB, Romanowski B, Roteli-Martins CM, . Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet. 2006;367: 1247–55.
- Villa LL, Costa RL, Petta CA, Andrade RP, Ault KA, Giuliano AR, . Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol. 2005;6:271–8.
- Mao C, Koutsky LA, Ault KA, Wheeler CM, Brown DR, Wiley DJ, Alvarez . Efficacy of human papillomavirus-16 vaccine to prevent cervical intraepithelial neoplasia: a randomized controlled trial. Obstet Gynecol. 2006;107:18–27.
- Munoz N, Manalastas R Jr, Pitisuttithum P, Tresukosol D, Monsonego J, Ault K, . Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24–45 years: a randomised, double-blind trial. Lancet. 2009;373:1949–57.
- Bishop NJ, Morley R, Day JP, Lucas A. Aluminum neurotoxicity in preterm infants receiving intravenous-feeding solutions. N Engl J Med. 1997;336:1557–61.
- Walton JR. Functional impairment in aged rats chronically exposed to human range dietary aluminum equivalents. Neurotoxicology. 2009;30: 182–93.
- Tomljenovic L. Aluminum and Alzheimer's disease: after a century of controversy, is there a plausible link? J Alzheimers Dis. 2011;23:567–98.
- Couette M, Boisse MF, Maison P, Brugieres P, Cesaro P, Chevalier X, . Long-term persistence of vaccine-derived aluminum hydroxide is associated with chronic cognitive dysfunction. J Inorg Biochem. 2009;103:1571–8.
- Authier FJ, Cherin P, Creange A, Bonnotte B, Ferrer X, Abdelmoumni A, . Central nervous system disease in patients with macrophagicmyofasciitis. Brain. 2001;124(Pt 5):974–83.
- Exley C, Swarbrick L, GherardiRK, AuthierFJ. A role for the body burden of aluminium in vaccine-associated macrophagicmyofasciitis and chronic fatigue syndrome. Med Hypotheses. 2009;72:135–9.
- Gherardi RK, Coquet M, Cherin P, Belec L, Moretto P, Dreyfus PA, Pellissier . Macrophagicmyofasciitis lesions assess long-term persistence of vaccine-derived aluminium hydroxide in muscle. Brain. 2001;124(Pt 9):1821–31.
- Shaw CA, PetrikMS. Aluminum hydroxide injections lead to motor deficits and motor neuron degeneration. J Inorg Biochem. 2009;103: 1555–62.
- Petrik MS, Wong MC, Tabata RC, Garry RF, Shaw CA. Aluminum adjuvant linked to Gulf War illness induces motor neuron death in mice. Neuromolecular Med. 2007;9:83–100.
- Tomljenovic L, Shaw CA. Do aluminum vaccine adjuvants contribute to the rising prevalence of autism? J Inorg Biochem. 2011;105:1489–99.
- Tomljenovic L, Shaw CA. Aluminum vaccine adjuvants: are they safe? Curr Med Chem. 2011;18:2630–7.
- Exley C. Aluminium-based adjuvants should not be used as placebos in clinical trials. Vaccine. 2011;29:9289.
- Merck&Co. Gardasil product sheet. Date of Approval 2006, p. 1–26 [cited 2011 July 25]. Available from: http://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM111263.pdf
- Lu B, Kumar A, Castellsague X, Giuliano AR. Efficacy and safety of prophylactic vaccines against cervical HPV infection and diseases among women: a systematic review & meta-analysis. BMC Infect Dis. 2011;11:13.
- Clifford GM, Smith JS, Plummer M, Munoz N, Franceschi S. Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis. Br J Cancer. 2003;88:63–73.
- Castle PE. Beyond human papillomavirus: the cervix, exogenous secondary factors, and the development of cervical precancer and cancer. J Low Genit Tract Dis. 2004;8:224–30.
- Harper DM, Nieminen P, Paavonen J, Lehtinen M. Cervical cancer incidence can increase despite HPV vaccination. Lancet Infect Dis. 2010;10:594–5; author reply 595.
- Lippman A, Melnychuk R, Shimmin C, Boscoe M. Human papillomavirus, vaccines and women's health: questions and cautions. CMAJ. 2007;177:484–7.
- Engeland A, Haldorsen T, Tretli S, Hakulinen T, Hörte LG, Luostarinen T, . Prediction of cancer mortality in the Nordic countries up to the years 2000 and 2010, on the basis of relative survival analysis. A collaborative study of the five Nordic Cancer Registries. APMIS Suppl. 1995;49:1–161.
- Laukkanen P, Koskela P, Pukkala E, Dillner J, Läärä E, Knekt P, . Time trends in incidence and prevalence of human papillomavirus type 6, 11 and 16 infections in Finland. J Gen Virol.2003;84(Pt 8): 2105–9.
- Fagot JP, Boutrelle A, Ricordeau P, Weill A, Allemand H. HPV vaccination in France: uptake, costs and issues for the National Health Insurance. Vaccine. 2011;29:3610–6.
- Sharma M, Ortendahl J, van der Ham E, Sy S, Kim J. Cost-effectiveness of human papillomavirus vaccination and cervical cancer screening in Thailand. BJOG. 2011 Apr 12. [Epub ahead of print]
- Kim JJ, Goldie SJ. Health and economic implications of HPV vaccination in the United States. N Engl J Med. 2008;359:821–32.
- Kim JJ, Goldie SJ. Cost effectiveness analysis of including boys in a human papillomavirus vaccination programme in the United States. BMJ. 2009;339:b3884.
- deKok IM, van Ballegooijen M, Habbema JD. Cost-effectiveness analysis of human papillomavirus vaccination in the Netherlands. J Natl Cancer Inst. 2009;101:1083–92.
- The New York Times. U.S. Approves Use of Vaccine for Cervical Cancer. June 9, 2006 [cited 2011 September 14]. Available from: http://www.nytimes.com/2006/06/09/health/09vaccine.html?fta = y
- Judicial Watch Special Report. Examining the FDA's HPV Vaccine Records Detailing the Approval Process, Side-Effects, Safety Concerns and Marketing Practices of a Large-Scale Public Health Experiment. June 30, 2008 [cited 2011 September 14]. Available from: http://www.judicialwatch.org/documents/2008/JWReportFDAhpvVaccineRecords.pdf
- Food and Drug Administration (FDA). FDA Science and Mission at Risk, Report of the Subcommittee on Science and Technology 2007 [cited 2010 December 12]. Available from: http://www.fda.gov/ohrms/dockets/ac/07/briefing/2007-4329b_02_01_FDA%20Report%20on%20Science%20and%20Technology.pdf
- Rothman SM, Rothman DJ. Marketing HPV vaccine: implications for adolescent health and medical professionalism. JAMA. 2009;302: 781–6.
- Sarojini NB, Srinivasan S, Madhavi Y, Srinivasan S, Shenoi A. The HPV vaccine: science, ethics and regulation. EconomPolit Weekly. 2010;45: 27–34.
- Sengupta A, Shenoi A, Sarojini NB, Madhavi Y. Human papillomavirus vaccine trials in India. Lancet Infect Dis. 2011;377:719.
- Legifrancegouv. Le Service Public De La Diffusion Du Droit. Décision du 31 août 2010 interdisantunepublicité pour un médicamentmentionnée à l'article L. 5122-1, premier alinéa, du code de la santé publiquedestinée aux personneshabilitées à prescrireoudélivrercesmédicamentsou à les utiliserdansl’exercice de leur art [cited 2011 January 26]. Available from: http://www.legifrance.gouv.fr/affichTexte.do;jsessionid = ?cidTex te = JORFTEXT000022839429&dateTexte&oldAction = rechJO&categorieLien = id
- McGee G, Johnson S. Has the spread of HPV vaccine marketing conveyed immunity to common sense? Am J Bioeth. 2007;7:1–2.
- Telethon Institute for Child Health Research. Perth women needed for international cervical cancer study, 12 April, 2006 [cited 2011 July 26]. Available from: http://www.ichr.uwa.edu.au/media/478
- World Medical Association (WMA) Declaration of Helsinki. Ethical Principles for Medical Research Involving Human Subjects [cited 2011 April 6]. Available from: http://www.wma.net/en/30publications/ 10policies/b3/
- WHO/ICO Information Centre on Human Papilloma Virus and Cervical Cancer [cited 2011 July 20]. Available from: http://apps.who.int/hpvcentre/statistics/dynamic/ico/SummaryReportsSelect.cfm
- Food and Drug Administration (FDA). CFR—Code of Federal Regulations Title 21 [cited 2011 September 19]. Available from: http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr = 314.80
- WHO/ICO HPV Information Centre. Human papillomavirus and related cancers. Summary report update. November 15, 2010 [cited 2011 July 21]. Available from: http://apps.who.int/hpvcentre/statistics/dynamic/ico/country_pdf/XWX.pdf?CFID = 5169709&CFTOKEN = 39667351